Does HIV-infection influence the response of chronic hepatitis C to interferon treatment? A French multicenter prospective study

Autor: H. Desmorat, F Bloch, Jacques Izopet, Daniel Fischer, B Mesnard, Pierre-Henri Bernard, François Bailly, J.-P. Lagasse, P. Couzigou, C Sayada, P Chossegros, G Force, Xavier Causse, Jean-Louis Payen, Marie-France Saint-Marc Girardin, J.C. Barbare, D Trois Vallets, Jean-Dominique Poveda, JC Schmit, Alexandre Pariente, P Sogni, Jean-Pierre Zarski, Albert Tran, Gérard Babany, L. Bettan, A Gauthier, Y Bacq, Eveline Boucher, Puig P Laurent, JM Lang, C Douvin, R Olivares, C Housset, Nathalie Boyer, W Rozenbaum, J.-J. Raabe, C Van Lemmens, O Danne, F. Montestruc
Rok vydání: 2000
Předmět:
Zdroj: Journal of Hepatology. 32:1003-1010
ISSN: 0168-8278
DOI: 10.1016/s0168-8278(00)80105-1
Popis: Background/Aim: The aim of this prospective study was to compare the response to alfa-interferon treatment of chronic hepatitis C in two groups of patients: coinfected with human immunodeficiency virus (HIV) (G I) or not (G II). Methods: One hundred and fifty-three patients with chronic hepatitis C had been enrolled in 30 French liver units or infectious diseases units between May 1992 and January 1995 (G I: 76, G II: 77) to receive alfa-2a interferon: 3 MU thrice weekly for 6 months. Results: One hundred and twenty-seven patients (G I: 63, G II: 64) fulfilled all criteria for analysis. The two groups were comparable for all demographic data, while significantly more severe biological and histological ( p =0.001) parameters attested to more serious hepatitis among HIV-HCV coinfected patients. HCV viremia was higher among HIV-coinfected patients ( p =0.0169), while genotype repartition was identical among the two groups (more than 52% of genotype 1, more than 31% of genotype 3). ALT normalization was, respectively, (G I/G II) obtained in 17.46%/26.56% (not significant) of patients at the end of treatment and in 11.11%/12.5% (not significant) of patients after 6 months of follow-up. In a multivariate analysis, GGT level before therapy (relative risk 2.1, confidence interval 1.1–5.8) and body surface area (relative risk 1.9, confidence interval 1.1–3.7) were the variables independently associated with the response to alfa-interferon treatment (higher GGT and more elevated body surface area were associated with a risk of non-response). Conclusion: In our study HIV infection did not affect the alfa-interferon treatment response of chronic hepatitis C, and response could be achieved among HIV-coinfected patients. Present therapeutic anti-HCV schedules need to be proposed to HIV-HCV coinfected patients before severe immunosuppression occurs. On the other hand, more severe biological and histological parameters were observed among HIV-HCV coinfected patients, which suggests a need to study whether HIV infection is associated with a worsening course of chronic hepatitis C.
Databáze: OpenAIRE
Externí odkaz: